$44.85
arrow_drop_down0.46%Key Stats | |
---|---|
Open | $45.56 |
Prev. Close | $45.06 |
EPS | -7.95 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 44.41 | 45.90 |
52 Week Range | 31.52 | 54.56 |
Ratios | |
---|---|
EPS | -7.95 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Leerink Partners upgrades Ionis stock on key asset commercialization - Investing.com
Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical - Benzinga
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.